Navigation Links
Men With Low Testosterone Not Receiving Treatment
Date:5/27/2008

Study finds patients with deficiency more likely to be poorer and without insurance

TUESDAY, May 27 (HealthDay News) -- Many men with low testosterone levels don't receive treatment, even though they have access to care, according to a U.S. study.

The study, which received funding from drug maker GlaxoSmithKline, was published in the May 26 issue of the journal Archives of Internal Medicine.

The research involved 97 Boston-area men with the low testosterone, also known as androgen deficiency. Only 11 were prescribed treatment. Treatments included: testosterone gel (one patient); testosterone patch (three patients); testosterone cream (one patient); an injectable form of testosterone called testosterone cypionate (one patient); and unspecified formulations of testosterone (five patients).

"All of the unspecified forms of testosterone used were self-reported as administered in intervals defined in weeks, which suggests that these were injectable formulations," wrote Susan A. Hall, of New England Research Institutes in Watertown, Mass., and colleagues.

Men with untreated androgen deficiency were most likely to have low socioeconomic status, no health insurance and to rely on an emergency department or hospital outpatient clinic for primary care, the study authors said.

They also found that all men with androgen deficiency (treated and untreated) were more likely than men without the condition to report receiving regular care and visiting their doctor more often -- 15.1 visits per year for those with untreated androgen deficiency, 12 visits for those with treated androgen deficiency, and 6.7 visits for those without the condition.

"Under our assumptions, a large majority (87.8 percent) of 97 men ... with androgen deficiency were not receiving treatment despite adequate access to care. The reasons for this are unknown but could be due to unrecognized androgen deficiency or unwilling
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Many men with low testosterone levels do not receive treatment
2. Testosterone Spray Improves Sexual Satisfaction in Women
3. Testosterone Levels Among Financial Traders Affect Performance
4. Testosterone Therapy May Reduce Bone Loss in Older Men
5. AUDIO from Medialink and Solvay Pharmaceuticals: Men with Type 2 Diabetes at Increased Risk for Low Testosterone Should Talk to Their Doctors
6. Older Men With Low Testosterone Face Greater Depression Risk
7. MSU research indicates testosterone could guard against eating disorders
8. Testosterone supplementation for older men appears to have limited benefit
9. Low Testosterone Might Shorten Mens Lives
10. The latest about male infertility and testosterone from NewYork-Presbyterian/Weill Cornell
11. 1 in 4 Men Over 30 Has Low Testosterone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2009)... -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... St. George,s Hospital, University of London during a ... ("ASH") Annual Meeting updated results from the pivotal ... pixantrone (the "PIX 301 EXTEND trial") in relapsed ... who have failed 2 or more prior therapies. ...
(Date:12/6/2009)... ORLEANS and SUNNYVALE, Calif., Dec. 6 ... interim results from a Phase I/II study showing ... / recurrent non-Hodgkin,s Lymphoma (NHL) treated with its ... data were presented today at the 51st ASH ... (Abstract # 2726). ,, PCI-24781 is an ...
(Date:12/6/2009)... of feline DNA in virus , , SUNDAY, Dec. 6 (HealthDay ... might be found in a tiger that lived thousands or ... appears the virus took on a bit of a tiger,s ... remains in the virus to this day. That tiger, in ... of the virus that ultimately led to its infection of ...
(Date:12/6/2009)... Hamilton, ON. Dec. 6, 2009 A new study ... disorder known as venous thromboembolism (VTE). , The ... Americans every year, and occurs when an abnormal clot ... blood, causing pain and swelling. In some cases, the ... travel through the heart to the lungs, causing a ...
(Date:12/5/2009)... ORLEANS, Dec. 5 There have been significant scientific ... experts continue to gain a better understanding of how ... options and provide patients with the best care. Research ... American Society of Hematology explores optimal induction therapies for ...
Breaking Medicine News(10 mins):Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5Health News:AIDS May Date Back to Ancient Tiger 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8
... pulmonary arterial hypertension (PAH)chronically high blood pressure in the ... low (called hyponatremia, or HN) have a very poor ... failure (RHF), according to new research from the University ... known to indicate advanced left heart failure but has ...
... of Lower Manhattan, the terrorist attacks of September 11, ... by the Health Department,s World Trade Center Health Registry, ... had posttraumatic stress disorder (PTSD) two to three years ... residents developed PTSD at three times the usual rate ...
... Valuable Patient Care,Resources in Manner True to Their Mission, ... from Los Angeles and Orange Counties demonstrated in front ... Thursday, June 12th to protest the,firm,s anti-union tactics aimed ... System (SJHS), a $3.4 billion dollar corporation,founded by the ...
... Bipartisan Package Would Have Improved Benefits for Prevention, ... CHICAGO, June 12 Today a minority ... and improve Medicare,for the 44 million Americans who ... Providers Act, which would have improved Medicare,s,prevention, mental ...
... A University of Alberta researcher in collaboration with researchers ... come with age, at least when it comes to ... Dolcos, assistant professor of psychiatry and neuroscience in the ... help healthy older people regulate and control emotion better ...
... (NYSE: GRB ), a worldwide leader in integrated ... investors on,Thursday, June 19, 2008, at 10:00 a.m. (Eastern ... financial results and provide a Company,update. The Company will ... and full year on June 19, 2008 before the ...
Other Medicine News:Health News:Serum sodium predicts mortality 10 times higher in PAH patients 2Health News:1 in 8 Lower Manhattan residents had signs of PTSD 2 to 3 years after 9/11 2Health News:Caregivers Protest Foley & Lardner's Union Busting & Intimidation 2Health News:Caregivers Protest Foley & Lardner's Union Busting & Intimidation 3Health News:AARP Disappointed by U.S. Senate Vote to Block Medicare Improvement Bill 2Health News:AARP Disappointed by U.S. Senate Vote to Block Medicare Improvement Bill 3Health News:New research shows how aging brain brings a healthy dose of perspective 2Health News:Gerber Scientific to Hold Fiscal Year 2008 Fourth Quarter and Full Year Conference Call 2
(Date:12/4/2009)... $2.8 million, four-year federal grant will support researchers at ... collaborators at Wake Forest University as they study why ... and how to address the problem. This "storage lesion," ... risk for cardiovascular events and organ failure, particularly among ...
(Date:12/4/2009)... Inc. (VRML) (Pink Sheets: VRMLQ) announced that on December 3, ... related amended Disclosure Statement with the United States Bankruptcy Court ... to consider the adequacy of the Disclosure Statement is presently ... confirmation of the Plan scheduled for January 7, 2010. ,, ...
(Date:12/4/2009)... (OTC Bulletin Board: OXBT) today announced that the first ... dose escalation, clinical trial in Switzerland for use of ... the Company,s perfluorocarbon (PFC) therapeutic oxygen carrier. ,, "This ... of patients with severe TBI. We hope to finally ...
Breaking Medicine Technology:NHLBI Grant Awarded to Wake Forest, Pitt to Improve Banked Blood 2NHLBI Grant Awarded to Wake Forest, Pitt to Improve Banked Blood 3Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2UCI researchers create new strategy for highly selective chemotherapy delivery 58290 1UCI researchers create new strategy for highly selective chemotherapy delivery 58290 2Siebel Foundation awards top UC San Diego bioengineering graduate students 10098 1Siebel Foundation awards top UC San Diego bioengineering graduate students 10098 2Siebel Foundation awards top UC San Diego bioengineering graduate students 10098 3Siebel Foundation awards top UC San Diego bioengineering graduate students 10098 4Nanoparticle based battlefield pain treatment moves a step closer 10094 1Nanoparticle based battlefield pain treatment moves a step closer 10094 2
... WIRE)--July 8, 2007 - Cougar Biotechnology,Inc. (OTCBB:CGRB) today ... on the Company's prostate cancer drug candidate CB7630,(abiraterone ... Oncology (ESMO) Conference, which is currently taking place,in ... oral and,poster presentations on Sunday, July 8, as ...
... Positive Phase IIa Clinical,Trial Results, First clinical ... in AM-Pharma's Pipeline , BUNNIK, The Netherlands, ... novel therapeutics to treat,infectious and inflammatory diseases, ... Phase IIa Alkaline Phosphatase (AP) trial,for patients ...
Other Medicine Technology:Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 5Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 6AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5
An environmentally-safe, CN-free lytic reagent designed for use on the Abbott CELL-DYN® 1800 three-part differential hematology analyzer....
... Para 12 Plus is a hematology control ... 3500/3700. Assay values are provided for the ... a three-part differential on the CELL-DYN 1600 ... and closed-vial stability is 75 days. Para ...
Indicated to facilitate the intra-luminal placement of conventional guidewires beyond stenotic lesions, including chronic total coronary occlusions....
... 5X is a whole blood hematology control ... 80 and 120, and the Coulter AcT5diff ... a unique white cell differential, positioning the ... on the systems. The product offers 105-day ...
Medicine Products: